




Hands-On Session: Core Lab Analysis

Gary S Mintz, MD

*Cardiovascular Research Foundation
New York City*




Stented Artery



**Proximal
Reference**

**Lesion
Site**

**Distal
Reference**



EEM CSA = 20.4
Lumen CSA = 9.7
Max lumen diam = 3.7
MLD = 3.1
P+M CSA = 10.7
Eccentricity = 1.0/0.3
Plaque burden = 0.52
Arc of Ca = 60


EEM CSA = 21.6
Lumen CSA = 4.5
Max lumen diam = 32.8
MLD = 2.3
P+M CSA = 17.1
Eccentricity = 3.0/0.1
Plaque burden = 0.79

EEM CSA = 13.3
Lumen CSA = 8.9
Max lumen diam = 3.6
MLD = 3.0
P+M CSA = 4.4
Eccentricity = 0.6/0.2
Plaque burden = 0.33

Average Reference EEM CSA = 16.9
Remodeling Index = 1.3
Average Reference Lumen CSA = 9.3
Area Stenosis = 52%

CRF off-line analysis “Case report form”

S/U ID
 PATIENT ID
 PATIENT INITIALS



CARDIOVASCULAR RESEARCH FOUNDATION

TRIAL

INTRA-VASCULAR ULTRA-SOUND CASE REPORT FORM

IVUS CRF

INDEX – POST STENTING PROCEDURE

– IVU:

CREDIT: CARDIOVASCULAR RESEARCH FOUNDATION
 VERSION 1 - NOVEMBER 20, 2003

S/U ID
 PATIENT ID
 PATIENT INITIALS

INDEX IVUS

POST STENTING PROCEDURE **4/5**

QUANTITATIVE ANALYSIS

CASS #

QUANTITATIVE	PROXIMAL REFERENCE	<input type="checkbox"/> N/A	STENT	DISTAL REFERENCE	<input type="checkbox"/> N/A
IVUS FRAME # - START		<input type="checkbox"/> N/A	<input type="checkbox"/> N/A		<input type="checkbox"/> N/A
IVUS FRAME # - END		<input type="checkbox"/> N/A	<input type="checkbox"/> N/A		<input type="checkbox"/> N/A
LENGTH (MM)		<input type="checkbox"/> N/A	<input type="checkbox"/> N/A		<input type="checkbox"/> N/A
VESSEL VOLUME (MM ³)		<input type="checkbox"/> N/A	<input type="checkbox"/> N/A		<input type="checkbox"/> N/A
AVG VESSEL CSA (MM ²)		<input type="checkbox"/> N/A	<input type="checkbox"/> N/A		<input type="checkbox"/> N/A
VESSEL CSA AT MLA (MM ²)		<input type="checkbox"/> N/A	<input type="checkbox"/> N/A		<input type="checkbox"/> N/A
MIN VESSEL DIAMETER (MM)		<input type="checkbox"/> N/A	<input type="checkbox"/> N/A		<input type="checkbox"/> N/A
MAX VESSEL DIAMETER (MM)		<input type="checkbox"/> N/A	<input type="checkbox"/> N/A		<input type="checkbox"/> N/A
AVG VESSEL DIAMETER (MM)		<input type="checkbox"/> N/A	<input type="checkbox"/> N/A		<input type="checkbox"/> N/A
STENT VOLUME (MM ³)			<input type="checkbox"/> N/A		
AVG STENT CSA (MM ²)			<input type="checkbox"/> N/A		
STENT CSA AT MLA (MM ²)			<input type="checkbox"/> N/A		
MIN STENT DIAMETER (MM)			<input type="checkbox"/> N/A		
MAX STENT DIAMETER (MM)			<input type="checkbox"/> N/A		
AVG STENT DIAMETER (MM)			<input type="checkbox"/> N/A		
LEMEN VOLUME (MM ³)		<input type="checkbox"/> N/A	<input type="checkbox"/> N/A		<input type="checkbox"/> N/A
AVG LEMEN CSA (MM ²)		<input type="checkbox"/> N/A	<input type="checkbox"/> N/A		<input type="checkbox"/> N/A
MINIMAL LEMEN AREA (MM ²)		<input type="checkbox"/> N/A	<input type="checkbox"/> N/A		<input type="checkbox"/> N/A
FRAME NUMBER OF MLA		<input type="checkbox"/> N/A	<input type="checkbox"/> N/A		<input type="checkbox"/> N/A

CREDIT: CARDIOVASCULAR RESEARCH FOUNDATION
 VERSION 1 - NOVEMBER 20, 2003

11 pages!!!

- **What you analyze and how you analyze it depends on the question that you want to answer.**
- **It is important to have the question or hypothesis in mind before you start your analysis and, even better, before you collect your data**
 - **IVUS predictors of ischemia or events**
 - **IVUS predictors of restenosis or stent thrombosis**
 - **Mechanisms of restenosis**
 - **Progression/regression**

- **Pre-specify the analysis and definitions. This is especially important in unblinded and non-randomized studies.**
- **Analysis software**
 - **Commercial systems**
 - **Freeware/shareware. . . NIH Image (or ImageJ for Mac)**
- **Understand the limitations of your project before you start**
- **The more you plan in advance, the less you will have to repeat before you are finished.**
- **Read the literature. Standards documents exist. Read them and follow their guidelines.**



VERDICT Pilot

Vascular Evaluation for Revascularization: Defining Indications for Coronary Therapy

Prospective, multicenter, non-randomized, non-blinded study in 300 intermediate coronary lesions

(DS $\geq 40\%$ - $< 80\%$, RVD 2.75 – 4.0 mm)

FFR and VH-IVUS assessment of all lesions

10 sites in US and EU; Sponsor: Volcano Corp.

Study Endpoints and Objectives:

1. Examine concordance between FFR and VH-IVUS parameters
2. Establish IVUS values for MLA/length/volume to predict ischemia (ROC)
3. ? Incremental correlative value of fibroatheromas for ischemia
4. Inform a large-scale, randomized trial

VERDICT Randomized Trial

Patients undergoing PCI with one or more additional intermediate lesions ($\geq 40\%$ - $< 80\%$) in a vessel with RVD 2.75 - 4.0 mm

R

Selective interrogation and proscribed deferral

Angiographic
guidance

FFR
guidance

VH-IVUS
guidance

1 year follow-up

Endpoints: MACE, cost-effectiveness


Powered for superiority of both FFR and VH-IVUS vs. angio ($\alpha=0.025$)

Note: Trial design not finalized

Assessment of Predictors of Thrombosis & Restenosis

	DES Thrombosis	DES Restenosis
Underexpansion	<ul style="list-style-type: none"> • Fujii et al. <i>J Am Coll Cardiol</i> 2005;45:995-8) • Okabe et al., <i>Am J Cardiol.</i> 2007;100:615-20 • Liu et al. <i>JACC Cardiovasc Interv.</i> 2009;2:428-34 • Choi et al. <i>Circulation Cardiovascular Interventions (in press)</i> 	<ul style="list-style-type: none"> • Sonoda et al. <i>J Am Coll Cardiol</i> 2004;43:1959-63 • Hong et al. <i>Eur Heart J</i> 2006;27:1305-10 • Doi et al <i>JACC Cardiovasc Interv.</i> 2009;2:1269-75 • Fujii et al. <i>Circulation</i> 2004;109:1085-1088
Edge problems (geographic miss, secondary lesions, large plaque burden, etc)	<ul style="list-style-type: none"> • Fujii et al. <i>J Am Coll Cardiol</i> 2005;45:995-8) • Okabe et al., <i>Am J Cardiol.</i> 2007;100:615-20 • Liu et al. <i>JACC Cardiovasc Interv.</i> 2009;2:428-34 • Choi et al. <i>Circulation Cardiovascular Interventions (in press)</i> 	<ul style="list-style-type: none"> • Sakurai et al. <i>Am J Cardiol</i> 2005;96:1251-3 • Liu et al. <i>Am J Cardiol</i> 2009;103:501-6 • Costa et al, <i>Am J Cardiol,</i> 2008;101:1704-11

Impact of lesion length and final minimum stent area (MSA) on restenosis



**No actual observations in this range*

de Feyter et al. *Circulation* 1999;100:1777-83

	ST	No ST	p
Reference segment			
Most normal looking			
Lumen CSA, mm ²	9.2	9.3	0.6
EEM CSA, mm ²	14.4	15.3	0.7
Plaque burden, %	41.7	37.0	0.3
Most diseased			
Lumen CSA, mm ²	3.5	5.9	<0.001
EEM CSA, mm ²	13.5	12.2	0.8
Plaque burden, %	67.5	49.5	<0.001
Stent			
MLA slice			
Stent CSA, mm ²	6.3	7.1	0.5
Lumen CSA, mm ²	4.4	6.7	0.013
MSA slice			
Stent CSA, mm ²	6.3	7.1	0.3
<5.0mm ²	41.7%	17.0%	


Assessment of Mechanisms of Restenosis

- Identify the site of the minimum lumen CSA at follow-up because this defines restenosis. Then “go backwards” to identify the same cross-section post-PCI and pre-PCI
- Conversely, it is not correct to identify the site of the minimum lumen CSA pre-PCI and “go forward” to identify the same cross-section post-PCI and at follow-up. This may not represent the restenosis process.
- The MLA migrates from pre-PCI to post-PCI to follow-up.

What measurements are important?

Non-stented lesions	Stented lesions	Stent edges
ΔEEM	ΔStent	ΔEEM
ΔLumen	ΔLumen	ΔLumen
ΔP&M	ΔIH	ΔP&M
	ΔEEM	
	ΔP&M	
	ΔMalapposition	

Volumetric analysis and planar (mm x mm) analysis are complementary





analysis of proximal edge

analysis in-stent

analysis of distal edge

%IH in various DES trials





Mechanism of Lumen Enlargement During Intracoronary Stent Implantation


Ahmed et al. *Circulation* 2000;102:7-10

Serial edge analysis in TAXUS-II


Proximal edge

Stent

Distal edge




Serruys et al. Circulation 2004;109:627-33




Stent and Edges per mm

- Lumen loss
- Plaque gain
- Remodeling




Stent and Edges per mm





Stent and Edges per mm

*** 20% incidence of late malapposition**



Weissman et al unpublished
 Kay et al. Circulation 2001;103:14-7

Location of 273 ruptured plaques in 158 patients with ACS and 48 patients with stable angina and three vessel IVUS



ACC CLINICAL EXPERT CONSENSUS DOCUMENT

American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS)

A Report of the American College of Cardiology
Task Force on Clinical Expert Consensus Documents
Developed in Collaboration with the European Society of Cardiology
Endorsed by the Society of Cardiac Angiography and Interventions

WRITING COMMITTEE MEMBERS

GARY S. MINTZ, MD, FACC and STEVEN E. NISSEN, MD, FACC, *Co-Chairs*

WILLIAM D. ANDERSON, MD, FACC
STEVEN R. BAILEY, MD, FACC
RAIMUND ERBEL, MD, FESC, FACC*
PETER J. FITZGERALD, MD, PhD, FACC
FAUSTO J. PINTO, MD, PhD, FESC, FACC*

KENNETH ROSENFELD, MD, FACC
ROBERT J. SIEGEL, MD, FACC
E. MURAT TUZCU, MD, FACC
PAUL G. YOCK, MD, FACC

TASK FORCE MEMBERS

ROBERT A. O'ROURKE, MD, FACC, *Chair*

JONATHAN ABRAMS, MD, FACC
ERIC R. BATES, MD, FACC
BRUCE R. BRODIE, MD, FACC
PAMELA S. DOUGLAS, MD, FACC
GABRIEL GREGORATOS, MD, FACC

MARK A. HLATKY, MD, FACC
JUDITH S. HOCHMAN, MD, FACC
SANJIV KAUL, MBBS, FACC
CYNTHIA M. TRACY, MD, FACC
DAVID D. WATERS, MD, FACC

WILLIAM L. WINTERS, JR., MD, MACC

TABLE OF CONTENTS

Preamble.....	1479
I. Introduction.....	1479
A. Organization of Committee and Evidence Review.....	1479
B. Purpose of This Document.....	1479
II. Physical Principles of IVUS Imaging.....	1480

When citing this document, the American College of Cardiology would appreciate the following citation format: Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, Pinto FJ, Rosenfield K, Siegel RJ, Tuzcu EM, Yock PG. ACC Clinical Expert Consensus Document on Standards for the acquisition, measurement and reporting of intravascular ultrasound studies: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents (Committee to Develop a Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies [IVUS]). *J Am Coll Cardiol* 2001;37:1479-92.

*Official representatives of the European Society of Cardiology.
Address for reprints: This document is available on the ACC Website at www.acc.org.
Reprints of this document are available for \$3.00 each by calling 800-233-4636 (T, U, only) or writing to the Resource Center, American College of Cardiology, Educational Services, 9111 Old Georgetown Road, Bethesda, MD 20814-1699.

III. Equipment for IVUS Examination.....	1480
A. Mechanical Systems.....	1480
B. Electronic Systems.....	1480
IV. IVUS Artifacts.....	1480
A. Non-Uniform Rotational Distortion (NURD) and Motion Artifacts.....	1480
B. Ring-Down, Blood Speckle, and Near Field Artifacts.....	1481
C. Obliquity, Eccentricity, and Problems of Vessel Curvature.....	1481
D. Problem of Spatial Orientation.....	1481
V. Controls for Image Acquisition.....	1481
A. Gain and TGC.....	1481
B. Compression and Rejection.....	1481
C. Time-Averaging and Persistence.....	1481
D. Gamma Curves.....	1482
VI. Acquisition and Display Techniques.....	1482
A. Manual and Motorized Interrogation.....	1482
B. Longitudinal Display (L-Mode).....	1482

Downloaded from content.onlinejacc.org by George Dangas on October 25, 2010

Use well-established greyscale IVUS definitions and measurements

Don't re-invent the wheel!

Clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound regression/progression studies

Gary S. Mintz¹, MD; Hector M. Garcia-Garcia^{2,3}, MD, MSc; Stephen J. Nicholls^{4,5,6}, MBBS, PhD; Neil J. Weissman⁷, MD; Nico Bruining⁸, MD, PhD; Tim Crowe⁹, BS; Jean-Claude Tardif⁹, MD; Patrick W. Serruys^{2*}, MD, PhD

1. Cardiovascular Research Foundation, New York, NY, USA; 2. Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands; 3. Cardiology, Rotterdam, The Netherlands; 4. Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA; 5. Department of Cell Biology, Cleveland Clinic, Cleveland, OH, USA; 6. Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic, Cleveland, OH, USA; 7. MedStar Research Institute, Washington Hospital Center, Washington DC, USA; 8. Department of Medicine, Montreal Heart Institute, Montreal, Canada

Gary Mintz received grant support, fellowship support and honoraria from Boston Scientific and Hitachi Corporation. Steven Nichols received honoraria from Pfizer, AstraZeneca, Takeda and Merck Schering-Plough; consultancy fees from AstraZeneca, Abbott, Pfizer, Roche, Novartis, Merck Schering-Plough, Lipitor and Amgen Pharmaceuticals and research support from AstraZeneca, Lead Sciences, Novartis and Biogen. Neil Weissman received grant support from Boston Scientific; lead sponsor and GSA. The following authors have no conflicts of interest to declare: Hector M. Garcia-Garcia.

* Nico Bruining, Genevieve van der Meer, Arno de Boer, Marie-Ange Morel, Tim Crowe, Jean-Claude Tardif and Patrick W. Serruys.

Rationale for a consensus document

Atherosclerotic cardiovascular disease is a leading cause of morbidity and mortality despite the widespread use of established medical therapies. This has prompted the search to identify new therapeutic approaches to achieve more effective prevention of cardiovascular events. Considerable interest has focused on the role of surrogate markers of therapeutic efficacy in the early evaluation of novel anti-atherosclerotic therapies.

Monitoring changes in the extent of coronary atherosclerosis with intravascular ultrasound (IVUS) has been increasingly employed in clinical trials to assess progression and regression of atherosclerosis. This is based on the pivotal role that atherosclerotic plaque plays in the natural history of cardiovascular disease and the acceptance of validated arterial imaging approaches including coronary angiography and carotid intimal-medial thickness by regulatory authorities. The ability to generate high-resolution imaging of the entire thickness of the coronary artery wall permits evaluation of the entire burden of atherosclerotic plaque.

In order to understand the differences, similarities, limitations and pitfalls of the IVUS technique among different academic core

laboratories, a number of meetings of representatives from these groups were convened in 2007 and 2008. This document is the result of those IVUS methodology meetings that assembled experts from core laboratories to discuss standards for image acquisition, definitions, criteria, analyses, and primary and secondary endpoints.

Equipment

Early studies that employed coronary IVUS imaging typically involved the use of one imaging system in terms of both catheter and console. With technological advances a number of systems and catheters are now available that permit high-resolution imaging within the coronary arteries. Given that studies often involve a large network of sites, there is likely to be marked heterogeneity in terms of imaging systems available among institutions and within each catheterisation laboratory. As a result, there is now a much greater risk that an individual subject is imaged with different systems at different time points. It is critical that every possible effort is made to ensure that an individual is imaged with the same equipment (catheters and consoles and pullback devices) for baseline and follow-up studies.

* Corresponding author: BaSEBd, Thoraxcenter, Erasmus MC, 3-Gevensdijfwal 200, 3015 CE Rotterdam, The Netherlands

E-mail: p.w.j.c.serruys@erasmusmc.nl

© Europe Edition 2010. All rights reserved.

- Use the absolute change in % atheroma volume of a >30mm long segment with well-defined proximal and distal fiducial points as the primary endpoint
- Even though the most diseased subsegments contain the largest mean plaque burden, do not use for the primary endpoint:
 - No consistent proximal and distal fiducial points
 - MLA, maximum plaque burden, and the most-diseased segment can shift during follow-up
 - variability increases when the segment length is short

Tissue characterisation using intravascular radiofrequency data analysis: recommendations for acquisition, analysis, interpretation and reporting

Héctor M. García-García¹, MD, MSc; Gary S. Mintz², MD, FACC; Amir Lerman³, MD, FACC; D. Geoffrey Vince⁴, PhD; M. Paulina Margolis⁴, MD, PhD; Gerrit-Anne van Es⁵, PhD; Marie-Angèle M. Morel⁶, BSc; Anuja Nair⁴, PhD; Renu Virmani⁶, MD, FACC; Allen P. Burke⁶, MD, FACC; Gregg W. Stone², MD, FACC; Patrick W. Serruys^{1*}, MD, PhD, FACC, FESC

1. Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands; 2. Cardiovascular Research Foundation, New York, USA; 3. Mayo Clinic, Rochester, Minnesota, USA; 4. Volcano Corporation, Rancho Cordova, California, USA; 5. Cordialexis, BV, Rotterdam, The Netherlands; 6. CVPath Institute, Inc., Gaithersburg, Maryland, USA

Paulina Margolis is vice president of scientific affairs and medical director of Volcano Corporation. She and her husband declare ownership interest. D. Geoffrey Vince and Anuja Nair are also Volcano Corporation employees. Gary Mintz declares ownership interest and is also a consultant of the company. Renu Virmani is consultant to Volcano Corporation and she and her husband research support from Volcano Corporation. Gregg Stone is consultant to Volcano Corporation. He has received research support from Boston Scientific and Abbott Vascular.

KEYWORDS


Imaging, patients, plaque, radiofrequency data analysis, ultrasonics

Abstract


This document suggests standards for the acquisition, measurement, and reporting of radiofrequency data analysis (virtual histology - VH) intravascular ultrasound (IVUS) studies. Readers should view this document as the authors' best attempt in an area of rapidly evolving investigation, an area where rigorous evidence is not yet available or widely accepted. Nevertheless, this document is based on known pathologic data as well as previously reported imaging data; where practical, this data is summarised in the current document, a document which will also include recommendations for future evolution of the technology.

* Corresponding author: Department of Cardiology, Erasmus Medical Center, Thoraxcenter, 80563a, Erasmus MC, 3-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
E-mail: p.w.j.c.serruys@erasmusmc.nl
© Europe Edition. All rights reserved.


Thin-cap FA




Thick-cap FA




PIT



Fibrous



Fibrocalcific



Pre-specify the definitions

Catheterization and Cardiovascular Interventions 65:233–239 (2005)

Impact of Different Definitions on the Interpretation of Coronary Remodeling Determined by Intravascular Ultrasound

Kiyoshi Hibi,¹ MD, Michael R. Ward,¹ MD, Yasuhiro Honda,¹ MD, Takeshi Suzuki,¹ MD, Allen Jeremias,¹ MD, Hiroyuki Okura,¹ MD, Ali H.M. Hassan,¹ MD, Akiko Maehara,¹ MD, Alan C. Yeung,¹ MD, Gerard Pasterkamp,^{2,3} MD, Peter J. Fitzgerald,¹ MD, and Paul G. Yock,^{1,4} MD

The objective of this study was to compare the categorizations and determinants related to remodeling by the three definitions commonly used. Several morphological and intravascular ultrasound (IVUS) studies have demonstrated the fundamental importance of arterial remodeling in atherosclerosis. However, lack of consensus on how to define remodeling has led to conflicting analyses of factors that influence this process. Analysis of preinterventional IVUS images of 514 lesions in native coronary arteries was performed. Arterial remodeling was defined as outward by definition 1, when [cross-sectional area (CSA) of the external elastic membrane (EEM) at the lesion site (EEM_{lesion})]/[EEM CSA either at the proximal (EEM_{prox}) or distal (EEM_{distal}) reference site with the least amount of plaque] was > 1.05, intermediate when this ratio was between 0.95 and 1.05, and inward when < 0.95. Remodeling was defined as outward by definition 2 when EEM_{lesion} > both EEM_{prox} and EEM_{distal}. Inward when EEM_{lesion} < both EEM_{prox} and EEM_{distal}, and intermediate when EEM_{lesion} was intermediate between EEM_{prox} and EEM_{distal}. By definition 3, vessel remodeling was defined as outward when EEM_{lesion} > (EEM_{prox} + EEM_{distal})/2 and intermediate/inward when EEM_{lesion} ≤ (EEM_{prox} + EEM_{distal})/2. The frequency of outward remodeling was significantly higher by definitions 1 and 3 than by definition 2, whereas a higher frequency of inward remodeling was observed in definition 1, resulting in significantly different remodeling distributions between the three definitions ($P < 0.0001$). By multivariate logistic analysis, the only clinical determinants related to outward remodeling was younger age, and only by definition 3. IVUS determinants varied significantly between the three definitions. The only consistent determinants among the three definitions were smaller lumen CSA at the reference site and larger plaque + media CSA at the lesion site. This study demonstrates the significant impact of different remodeling definitions on the incidence and determinants of remodeling patterns. The marked variability in categorization of remodeling underscores the importance of developing a standard methodology. © 2005 Wiley-Liss, Inc.

Key words: atherosclerosis; coronary disease; ultrasonics

INTRODUCTION

Intravascular ultrasound (IVUS) studies have demonstrated that the remodeling response is critical in deter-

mining lumen size in de novo atherosclerosis [1,2] or in vessels after intervention [3–5]. Recent studies have indicated that outward remodeling may be associated

¹Division of Cardiovascular Medicine, Stanford University Medical Center, Stanford, California

²Department of Cardiology, Utrecht University Medical Center, Utrecht, The Netherlands

³Interuniversity Cardiology Institute of the Netherlands, Utrecht, The Netherlands

*Correspondence to: Dr. Paul G. Yock, Center for Research in Cardiovascular Interventions, Stanford University Medical Center, 300 Pasteur Drive, Room H3554, Stanford, CA 94305. E-mail: gyock@cardio.stanford.edu

© 2005 Wiley-Liss, Inc.

Received 17 July 2003; Revision accepted 31 January 2005

DOI: 10.1002/cvi.20566

Published online 5 April 2005 in Wiley InterScience (www.interscience.wiley.com).

236 Hibi et al.




Fig. 2. Frequency distribution and type of remodeling pattern for each remodeling definition.

inward remodeling in 198 (38.5%) lesions. By definition 3, outward remodeling was observed in 193 (37.5%) lesions and intermediate/inward remodeling in 321 (62.5%) lesions. There was a lower frequency of lesions with intermediate remodeling and a higher frequency of lesions with inward remodeling by definition 1 than by definition 2 ($P < 0.0001$). The frequency of lesions with outward remodeling was significantly higher by definition 1 and definition 3 than by definition 2 (both $P < 0.0001$).

Examples of categorization of lesion remodeling are shown in Figure 3. The lesion in the top panel was consistently defined as outward remodeling by all definitions (Fig. 3A). In contrast, the category of remodeling assigned to the lesion in the bottom panel was inconsistent (Fig. 3B). By definition 1, this lesion was assigned to inward remodeling using the proximal reference site to calculate the RL. The same lesion was assigned to intermediate remodeling by definition 2, whereas definition 3 defined this lesion as outward remodeling (Fig. 3B).

Determinants of Arterial Remodeling

The characteristics of the 514 lesions among the lesions with outward, intermediate, and inward remodeling are summarized in Table II. Only those parameters showing significant differences between groups by any of the three definitions are presented. When clinical variables were compared between vessel remodeling subgroups, no difference was noted. As expected from the definitions of remodeling patterns, lesions with outward remodeling had consistently larger P+M CSA and plaque burden at the lesion site than those with intermediate/inward remodeling ($P < 0.0001$ by any definition). Lumen CSAs at the reference site were consistently smaller in lesions with outward remodeling than in those with intermediate/inward remodeling




Fig. 3. Representative IVUS images of coronary arteries showing consistent (top) and inconsistent (bottom) remodeling pattern between the three remodeling definitions.

($P < 0.0001$ for definition 1, $P = 0.002$ for definition 2, and $P = 0.001$ for definition 3). Several parameters showed inconsistency between the three definitions for detecting the differences between remodeling subgroups: diseased vessel distributions, number of diseased vessels, P+M CSA at the reference site, plaque burden at the reference site, and lumen area stenosis (Table II).

By multivariate logistic analysis, the clinical and IVUS factors associated with positive remodeling varied significantly between the three definitions (Table III). Younger age and noncalcification at the lesion site were significantly associated with outward remodeling by definition 3 (odds ratio = 0.97 and 0.57, respectively); however, these factors did not remain significant by either definition 1 or definition 2. Similarly, left descending artery (LAD) lesion was associated with outward remodeling by definition 1 (odds ratio = 2.36), but not by definition 2 or 3. Smaller P+M CSA at the reference site was significantly associated with outward remodeling by definition 1 and definition 2 (odds ratio = 0.85 and 0.29, respectively), but not by definition 3. Furthermore, larger lumen CSA at the lesion site was significantly associated with outward remodeling by definition 2 only (odds ratio = 1.91). The only consistent associations with outward remodeling across all three definitions were smaller lumen CSA at the reference site and larger P+M CSA at the lesion site.

DISCUSSION

This study demonstrates that categorization and quantification of remodeling response is critically dependent on the method used to define remodeling. Consequently, correlation between remodeling response